• Increase font size
  • Default font size
  • Decrease font size
home | about us | contact us
Search
Search Only:

Search Keyword ADLS

Total: 50 results found.

... Aug. 30 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs ...
... (NASDAQ: ACCL), the leading scientific informatics software and services company, today announced the release of Symyx Notebook 6.5 by Accelrys. Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS), ...
...  CHICAGO, Aug. 24 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS), a biopharmaceutical company engaged in the discovery, ...
...  CHICAGO, Aug. 17 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS), a biopharmaceutical company engaged in the discovery, development ...
... of bribes being paid by pharmaceutical companies in foreign countries. Shares of SciClone fell $1.03 to close the day at $2.48. Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS.ob), a ...
... -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, ...
...  CHICAGO, Aug. 10 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS), a biopharmaceutical company ...
...  CHICAGO, Aug. 5 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS), a biopharmaceutical company engaged in the discovery, ...
... -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS) today announced that it will host a conference call and live webcast at 9:00 a.m. Eastern Time on Wednesday, August 11, 2010 to discuss ...
... 33% on the news, rising $3.14 to $12.47. Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS.ob), a biopharmaceutical company engaged in the discovery, development and commercialization of ...
11. Advanced Life Sciences Turning Around
(Home Page/Home Page)
It appears that after several months of decline, Advanced Life Sciences Inc. (OTC:ADLS.OB) appears to be headed in a positive direction. Recent developments in the Restanza(tm) pipeline are now starting ...
... for products of this kind. Shares of ISCO surged more than 22% or 25 cents, closing the day at $1.37. Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS.ob), a biopharmaceutical company ...
... (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, ...
... the technology when it begins international expansion. Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS.ob), a biopharmaceutical company engaged in the discovery, development and commercialization ...
...  CHICAGO, July 26 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development ...
... Injection (Suspension with Albumin), for use in the treatment of breast cancer. Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, ...
... Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced ...
... Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory ...
CHICAGO-- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas ...
... -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, ...
... -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company developing Restanza™, a novel once-a-day oral antibiotic, today announced that it has submitted a ...
... June 9 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs ...
... called phosphatidylserine to reactivate the immune system response." Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS.ob), a biopharmaceutical company engaged in the discovery, development ...
...  CHICAGO, May 28 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), ...
...  CHICAGO, May 26 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a ...
... May 10 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs ...
... Holdings, Inc. (OTC Bulletin Board: ADLS), announced today that it will host a conference call and webcast discussing the Company's 2010 first quarter financial results on Monday, May 10, 2010 at 9:00 ...
...  CHICAGO, April 21 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) today announced positive results ...
...  CHICAGO, April 8 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), today announced the results from the Annual Meeting of Shareholders ...
... Report on Form 10-K. Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS.ob), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the ...
... Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, ...
Download image CHICAGO, March 11 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the dicovery, ...
Download image CHICAGO, March 4 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), announced today that it will host a conferece call ...
... -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, ...
35. RxNews Recap for Wednesday 11-04-09
(Home Page/Home Page)
... Inc. (OTC:ADLS), announced it will host a conference call and webcast discussing the Company's 2009 third quarter results on Tuesday, November 10, 2009 at 10:00 a.m. (EST). InterMune, Inc. (Nasdaq:ITMN) ...
36. FDA Calendar Extreme Trades: 85 Single Digit Stocks
(Premium Content/Subscriber Only Content)
... the end of the year.   6.) On 9/29/09, Advanced Life Sciences (OTC: ADLS.OB) ($0.275) announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral ...
37. FDA Calendar Updates: Delcath, Pozen, Advanced Life Sciences
(Premium Content/Subscriber Only Content)
... exposure.   On 8/31/09, ADLS.ob announced positive results from an animal study involving its novel, once-a-day, oral antibiotic Restanza (cethromycin) that was conducted to measure its therapeutic ...
... compounds from Novogen. On 7/31/09, (21) Advanced Life Sciences (ADLS.OB) ($0.48) announced that it received a complete response letter (CRL) from the FDA for the Company's New Drug Application (NDA) ...
... 7/31/09, (21) Advanced Life Sciences (ADLS.OB) ($0.48) announced that it received a complete response letter (CRL) from the FDA for the Company's New Drug Application (NDA) for Restanza (cethromycin) for ...
... Advanced Life Sciences (ADLS.OB) announced that it received a complete response letter (CRL) from the FDA for the Company's New Drug Application (NDA) for Restanza (cethromycin) for the outpatient treatment ...
... Life Sciences (ADLS.OB) announced that it received a complete response letter (CRL) from the FDA for the Company's New Drug Application (NDA) for Restanza (cethromycin) for the outpatient treatment of ...
... FDA, which will increase to US$20 million if certain labeling criteria are agreed to by the FDA. Advanced Life Sciences (OTC:ADLS) ($0.46): Cethromycin NDA (a once-daily antibiotic for the treatment ...
... FDA, which will increase to US$20 million if certain labeling criteria are agreed to by the FDA. Advanced Life Sciences (OTC:ADLS) ($0.46): Cethromycin NDA (a once-daily antibiotic for the treatment of ...
... Trials Calendar, look for Advanced Life Sciences Holdings, Inc. (OTC: ADLS) shares to continue to rise after the company today announced that a second non-human primate study involving its novel, once-a-day, ...
... a new formulation of an existing drug for the proposed treatment of major depressive disorder with an estimated PDUFA action date of 7/18/09 for a possible FDA decision. Advanced Life Sciences (NASDAQ:ADLS): ...
... drug for the proposed treatment of major depressive disorder with an estimated PDUFA action date of 7/18/09 for a possible FDA decision. Advanced Life Sciences (NASDAQ:ADLS): Cethromycin NDA (a once-daily ...
Calls and emails flooded in from subscribers holding shares of Advanced Life Sciences (OTC:ADLS). They wondered what the catalyst was for the stock price plunge- from $1.60 to $.25 on heavy trading Tuesday ...
... these data as the second of two positive registration studies in support of a New Drug Application (NDA) with the FDA for vilazodone for the treatment of MDD by the end of 2009. Advanced Life Sciences (OTC:ADLS) ...
... these data as the second of two positive registration studies in support of a New Drug Application (NDA) with the FDA for vilazodone for the treatment of MDD by the end of 2009. Advanced Life Sciences (OTC:ADLS) ...
... reviewed by the FDA before issuing the CRL) may address several of the deficiencies raised by FDA and may limit the need for some of the actions specified in the letter. Advanced Life Sciences (OTC:ADLS): ...

Get Free Email and Phone News Alerts

* Your email address:
* Preferred Format:
* Enter the security code shown:
 
Home | Privacy Policy
© 2010 BioMedReports.com. All rights reserved